HK Stock Market Move | DUALITYBIO-B (09606) surged more than 4% in late trading, achieving a new breakthrough in collaboration with Roche, with a potential milestone amount exceeding $1 billion.

DUALITYBIO-B (09606) rose over 4% in the final trading hours. As of the time of writing, it increased by 3.56%, reaching HKD 186.4, with a trading volume of HKD 194 million. In terms of news, recently, Eien Biopharma signed a collaboration and licensing agreement with Genentech, a subsidiary of Roche Group, to develop multiple next-generation ADC drugs targeting various cancer indications based on the company's DUPAC platform. According to the collaboration agreement, Eien Biopharma will receive an upfront payment of USD 45 million and is eligible for potential development, regulatory, and commercialization milestone payments exceeding USD 1 billion for all collaboration projects. Additionally, the company will have the right to receive tiered royalties on the annual net sales of the approved products generated from the collaboration. China Securities Co., Ltd. released a research report stating that the company is a leading domestic innovative ADC drug research and development platform and has established four major technology platforms: DITAC, DIMAC, DIBAC, and DUPAC. DB-1311 has entered global Phase III clinical trials and is actively expanding in ADC+IO2.0 combination therapies and multiple tumor indications; DB-1303 is gradually entering the registration phase, with innovative pipelines such as DB-1418, DB-1317, and DB-2304 continuing to advance. Meanwhile, the company has formed collaborations with several global pharmaceutical companies, making upfront payments, milestone payments, and potential sales sharing expected to constitute a long-term revenue source.